Next Article in Journal
On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent Resistance
Previous Article in Journal
Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines 2019, 7, 69
Open AccessArticle

Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma

Human Health Therapeutics, National Research Council of Canada, Montreal Rd. 1200, Ottawa, ON K1A 0R6, Canada
*
Author to whom correspondence should be addressed.
Biomedicines 2019, 7(4), 91; https://doi.org/10.3390/biomedicines7040091
Received: 16 September 2019 / Revised: 6 November 2019 / Accepted: 13 November 2019 / Published: 23 November 2019
Archaeosomes are liposomes composed of natural or synthetic archaeal lipids that when used as adjuvants induce strong long-lasting humoral and cell-mediated immune responses against entrapped antigens. However, traditional entrapped archaeosome formulations have only low entrapment efficiency, therefore we have developed a novel admixed formulation which offers many advantages, including reduced loss of antigen, consistency of batch-to-batch production as well as providing the option to formulate the vaccine immediately before use, which is beneficial for next generation cancer therapy platforms that include patient specific neo-antigens or for use with antigens that are less stable. Herein, we demonstrate that, when used in combination with anti-CTLA-4 and anti-PD-1 checkpoint therapy, this novel admixed archaeosome formulation, comprised of preformed sulfated lactosyl archaeol (SLA) archaeosomes admixed with OVA antigen (SLA–OVA (adm)), was as effective at inducing strong CD8+ T cell responses and protection from a B16-OVA melanoma tumor challenge as the traditionally formulated archaeosomes with encapsulated OVA protein. Furthermore, archaeosome vaccine formulations combined with anti-CTLA-4 and anti-PD-1 therapy, induced OVA-CD8+ T cells within the tumor and immunohistochemical analysis revealed the presence of CD8+ T cells associated with dying or dead tumor cells as well as within or around tumor blood vessels. Overall, archaeosomes constitute an attractive option for use with combinatorial checkpoint inhibitor cancer therapy platforms. View Full-Text
Keywords: cancer; immunotherapy; checkpoint; PD-1; CTLA-4; archaeal; archaeosomes; vaccine; adjuvant; melanoma; TIL; tumor infiltrating lymphocyte cancer; immunotherapy; checkpoint; PD-1; CTLA-4; archaeal; archaeosomes; vaccine; adjuvant; melanoma; TIL; tumor infiltrating lymphocyte
Show Figures

Graphical abstract

MDPI and ACS Style

Stark, F.C.; Agbayani, G.; Sandhu, J.K.; Akache, B.; McPherson, C.; Deschatelets, L.; Dudani, R.; Hewitt, M.; Jia, Y.; Krishnan, L.; McCluskie, M.J. Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma. Biomedicines 2019, 7, 91.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop